Sage Therapeutics (SAGE) : Traders are bullish on Sage Therapeutics (SAGE) as it has outperformed the S&P 500 by a wide margin of 22.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.96%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.56% in the last 1 week, and is up 20.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 13.01% and the 50-Day Moving Average is 9.48%.The 200 Day SMA reached 15.63% Sage Therapeutics, Inc. is up 55.05% in the last 3-month period. Year-to-Date the stock performance stands at -24.68%.
Sage Therapeutics (SAGE) : The most positive equity analysts on Sage Therapeutics (SAGE) expects the shares to touch $95, whereas, the least positive believes that the stock will trade at $18 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $69 with an expected fluctuation of $28.96 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Sage Therapeutics (NASDAQ:SAGE): The stock opened at $43.09 and touched an intraday high of $44.05 on Friday. During the day, the stock corrected to an intraday low of $42.2, however, the bulls stepped in and pushed the price higher to close in the green at $43.91 with a gain of 1.50% for the day. The total traded volume for the day was 1,210,603. The stock had closed at $43.91 in the previous trading session.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.